Seattle Genetics, Inc. (NASDAQ:SGEN) CEO Clay B. Siegall sold 25,506 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $47.89, for a total transaction of $1,221,482.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Clay B. Siegall also recently made the following trade(s):

  • On Monday, August 7th, Clay B. Siegall sold 10,413 shares of Seattle Genetics stock. The shares were sold at an average price of $48.91, for a total transaction of $509,299.83.
  • On Wednesday, July 5th, Clay B. Siegall sold 10,423 shares of Seattle Genetics stock. The shares were sold at an average price of $51.98, for a total transaction of $541,787.54.
  • On Monday, June 5th, Clay B. Siegall sold 10,423 shares of Seattle Genetics stock. The shares were sold at an average price of $65.21, for a total transaction of $679,683.83.

Seattle Genetics, Inc. (SGEN) traded up 5.32% during mid-day trading on Thursday, reaching $52.43. 1,279,568 shares of the company were exchanged. Seattle Genetics, Inc. has a 1-year low of $43.71 and a 1-year high of $75.36. The stock has a 50-day moving average of $50.25 and a 200 day moving average of $60.29. The firm’s market capitalization is $7.50 billion.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The business had revenue of $108.20 million during the quarter, compared to analysts’ expectations of $105.92 million. During the same quarter in the prior year, the business earned ($0.23) earnings per share. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. Equities research analysts forecast that Seattle Genetics, Inc. will post ($1.69) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/31/seattle-genetics-inc-sgen-ceo-clay-b-siegall-sells-25506-shares-of-stock.html.

A number of analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Seattle Genetics in a report on Saturday, June 3rd. Cantor Fitzgerald set a $46.00 price target on shares of Seattle Genetics and gave the company a “hold” rating in a report on Wednesday, August 16th. Cann restated a “hold” rating on shares of Seattle Genetics in a report on Tuesday. Cowen and Company set a $61.00 price target on shares of Seattle Genetics and gave the company a “hold” rating in a report on Tuesday, June 6th. Finally, BidaskClub cut shares of Seattle Genetics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Five research analysts have rated the stock with a sell rating, ten have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $62.29.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Seattle Genetics by 2.3% in the second quarter. Vanguard Group Inc. now owns 7,530,515 shares of the biotechnology company’s stock valued at $389,628,000 after buying an additional 167,828 shares during the last quarter. BlackRock Inc. boosted its position in Seattle Genetics by 2.6% in the second quarter. BlackRock Inc. now owns 7,453,483 shares of the biotechnology company’s stock valued at $385,644,000 after buying an additional 185,823 shares during the last quarter. State Street Corp boosted its position in Seattle Genetics by 10.9% in the first quarter. State Street Corp now owns 2,845,120 shares of the biotechnology company’s stock valued at $178,847,000 after buying an additional 279,079 shares during the last quarter. Capital International Investors boosted its position in Seattle Genetics by 34.3% in the second quarter. Capital International Investors now owns 2,724,589 shares of the biotechnology company’s stock valued at $140,970,000 after buying an additional 695,986 shares during the last quarter. Finally, Matrix Capital Management Company LP boosted its position in Seattle Genetics by 18.8% in the second quarter. Matrix Capital Management Company LP now owns 2,118,000 shares of the biotechnology company’s stock valued at $109,585,000 after buying an additional 335,000 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.